Overview highlights current treatment modalities for malignant pleural mesothelioma, suggesting significant advancements.
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy primarily caused by asbestos exposure. Over the past decade, treatment strategies have evolved significantly, incorporating advancements in systemic therapies, immunotherapy, and personalized medicine. Multimodality treatment — integrating surgery, systemic therapy, and radiotherapy — may improve outcomes in carefully selected patients. This manuscript provides an overview of current treatment modalities for pleural mesothelioma (PM), emphasizing recent developments and emerging therapies.
No takes yet. Share an insight, caveat, or question.
Baldes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: